Key result
CYP2C19 clinical decision support alerts achieve only ~25% acceptance for post-PCI P2Y12 inhibitor selection.
Why the study?
Do interruptive clinical decision support (CDS) alerts increase the prescribing of alternative P2Y12 inhibitors in patients with decreased CYP2C19 function post-PCI?
Observational (n=362)
Do interruptive clinical decision support (CDS) alerts increase the prescribing of alternative P2Y12 inhibitors in patients with decreased CYP2C19 function post-PCI?
Interruptive CDS alerts for CYP2C19-clopidogrel interactions post-PCI resulted in modest adoption of genotype-guided P2Y12 inhibitor prescribing, with provider clinical judgment being the most common reason for override.
Answers are grounded in this paper and cite their sources.
Frequent CYP2C19 alert overrides for P2Y12 prescribing signal implementation barriers; leaves open optimal CDS design and prescriber rationale.
P2Y12 inhibitor selection involves numerous factors, including CYP2C19 genetics, since evidence demonstrates reduced clopidogrel efficacy in patients with decreased or no function CYP2C19 variants. In 2020, Indiana University health embedded interruptive clinical decision support (CDS) alerts in the electronic health record (EHR) to recommend alternative P2Y12 inhibitors for patients with decreased CYP2C19 function who had undergone percutaneous coronary intervention (PCI). The objective of this study was to evaluate prescriber response to these CDS alerts. Utilizing alert response data and P2Y12 inhibitor prescriptions from October 2020 to December 2023, we evaluated prescriber response for 362 patients who had a mean of 2.2 (SD: 1.7) CYP2C19‐clopidogrel alerts fire post‐PCI. Alert recommendations were accepted 24.5% ± 36.8% (mean ± SD) of the time. Alternative (i.e., non‐clopidogrel) P2Y12 inhibitors were prescribed for 22.4% ± 36.8% of days during the year following PCI. Alerts were accepted more for CYP2C19 poor metabolizers than for intermediate metabolizers (P = 0.03). Each year after 2020 was associated with a 4.6% increase in the days prescribed alternative P2Y12 inhibitors. In contrast, increasing age was associated with decreased alert acceptance and decreased percentage of days prescribed alternatives, and concomitant oral anticoagulant use was associated with decreased percentage of days prescribed alternatives. Provider clinical judgment was the most common alert override reason, accounting for 68% of clinician responses. Our findings demonstrate that CYP2C19‐clopidogrel CDS alerts promoted genotype‐guided P2Y12 inhibitor prescribing in some cases (~22% of study days). Future research should better determine prescriber reasons for rejecting alert recommendations and establish best implementation practices to complement CDS alerts.
No takes yet. Share an insight, caveat, or question.
Springer et al. (2025) conducted an observational in Decreased CYP2C19 function post-PCI (n=362). CYP2C19 clinical decision support (CDS) alerts was evaluated on Alert recommendation acceptance rate. CYP2C19-clopidogrel clinical decision support alerts were accepted 24.5% of the time, leading to alternative P2Y12 inhibitors being prescribed for 22.4% of days in the year following PCI.
Synapse has enriched 10 related papers. Consider them for comparative context: